In an editorial in Ophthalmology, the authors are very critical of the lack of scientific evidence for the notion that blue-blocking IOL’s can slow the progression of macular degeneration. They agree with the CMS that the relationship between blue light and AMD is speculative and not evidence-based. The authors make a compelling point. I look forward to the letters it will inspire. Since CMS won’t pay the $50 extra for these lenses anymore, perhaps they will fall out of favor.

I invite readers to post their own comments about their belief in the benefits, if any, of blue-blocking IOL’s.